TAVR is indicated in patients with severe symptomatic aortic stenosis in whom surgery is considered intermediate risk. In a retrospective study (2010-2014), 24% of patients were rehospitalized for heart failure (HF) one year after TAVI.

We aimed to assess the incidence, prognostic impact, and predictive factors of readmission for congestive heart failure (CHF) one year after TAVR in an intermediate risk population.

All patients who underwent transfemoral TAVR from mars 2018 to october 2018 were included. Prospective follow-up was achieved at 1 year and included, MACCE, readmission for CHF, clinical and echocardiographic data.

This study included 102 patients. Medial aging, sex ratio and medial logistic euroSCORE were respectively 85 [81–87] years, 50% and 13%[9-19,1]. One year after TAVR, 39 patients (39%) had been readmitted at least once, and 9 (9%) for CHF, one patient was readmitted twice. On multivariate analysis, a previous episode of CHF was the only factor close to be associated with CHF readmission at 1 year (hazard ratio: 10,52 (0,74–149,35), P=0.06).

The incidence of readmission for CHF decrease between 2014 and 2018. A previous episode of CHF is the only factor associated with CHF readmission in our study.